Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics (NYSE: HAE) will release third quarter fiscal 2026 results at 6:00 am ET on Thursday, February 5, 2026. The company will host a conference call with investors and analysts at 8:00 am ET on February 5, 2026, accessible by teleconference after registration, which provides a dial-in number and personalized PIN. A live webcast will be available on Haemonetics' investor relations website at the provided link. A replay of the conference call and webcast will be available for one year starting February 5, 2026 at 11:00 am ET. Participants are recommended to join the call 10 minutes early.
Haemonetics (NYSE: HAE) announced that President and CEO Chris Simon will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 AM PT.
The presentation will be available live via audio webcast at the provided JPMorgan link and under the Events & Presentations section of Haemonetics' Investor Relations website. A replay will be posted approximately one hour after the live event and will remain available for 30 days.
Haemonetics (NYSE: HAE) announced its second quarter fiscal 2026 financial results for the period ended September 27, 2025 are available on the company's Investor Relations website.
The company will host a live conference call and webcast with investors and analysts at 8:00 a.m. ET on November 6, 2025. A replay will be available beginning at 11:00 a.m. ET on November 6, 2025 and will remain accessible for one year via the webcast link. Earnings materials posted include the Second Quarter Fiscal 2026 Earnings Release and a Supplemental Earnings Presentation.
Haemonetics (NYSE: HAE) will publish Q2 fiscal 2026 results at 6:00 AM ET on Thursday, November 6, 2025. The company will host a conference call with investors and analysts at 8:00 AM ET on November 6, 2025 to discuss results and answer questions.
Participants must register for teleconference access and will receive a dial-in number and personalized PIN; joining 10 minutes early is recommended. A live webcast will be available on Haemonetics' investor relations website at the provided webcast link. A replay of the call and webcast will be available for one year beginning November 6, 2025 at 11:00 AM ET.
Haemonetics Corporation (NYSE: HAE) has announced the availability of its first quarter fiscal year 2026 financial results on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on August 7, 2025, at 8:00 a.m. ET to discuss the results.
The conference call requires pre-registration, and participants are recommended to join 10 minutes before the event. A replay of the conference call and webcast will be accessible for one year starting from August 7, 2025, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has scheduled the release of its first quarter fiscal year 2026 financial results for August 7, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and take questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start. A live webcast will be available on Haemonetics' investor relations website, with a replay accessible for one year starting August 7, 2025, at 11:00 am ET.
Vivasure Medical has announced two significant regulatory milestones for its PerQseal® Elite vascular closure system. The company has submitted a Premarket Approval (PMA) application to the FDA for arterial procedures and received European CE mark approval for expanded indication covering large-bore venous closure.
PerQseal Elite is positioned as the first fully bioresorbable, sutureless solution in Europe for both arterial and venous access closure. The system features a unique inside-vessel deployment mechanism and requires no pre-procedure steps, offering advantages over conventional closure techniques that leave behind materials like collagen, metal implants, or sutures.
Haemonetics Corporation (NYSE: HAE) has announced the availability of its fourth quarter and fiscal year 2025 financial results, which ended March 29, 2025, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on May 8, 2025, at 8:00 a.m. ET to discuss the results.
The company has provided access to supplemental materials including the earnings release and tables supporting fiscal 2026 total Company and Hospital reported and organic revenue growth guidance. A replay of the conference call will be available for one year starting May 8, 2025, at 11:00 a.m. ET.
Vivasure Medical has received CE Mark approval for its PerQseal Elite vascular closure system, a pioneering fully absorbable and sutureless large-bore vessel closure device. The product will be launched in select European markets this summer.
The PerQseal Elite system is specifically designed for closure following large-bore percutaneous cardiovascular procedures like TAVR and EVAR. It stands out as the first fully bioresorbable device in this category and requires no pre-procedure steps, offering improved procedural efficiency.
The device is placed from inside the vessel, providing simpler and more controlled deployment compared to conventional techniques. It restores the vessel to its natural state without leaving behind materials such as collagen, metal implants, or sutures.